Yescarta

Celgene posts pivotal CAR-T data ahead of FDA filing
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
Flag link:
Gilead third-quarter results in line, but Yescarta sales dip
Gilead third-quarter results in line, but Yescarta sales dip
Yahoo/Reuters
Gilead Sciences
earnings
Yescarta
Flag link:
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Yahoo/Reuters
lymphoma
Gilead Siences
Novartis
cell therapies
Kymriah
Yescarta
Flag link:
Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly
Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly
Fierce Pharma
Gilead Sciences
Kte Pharma
Yescarta
CAR-T
cell therapy
Flag link:
Gilead highlights Yescarta survival data in ASCO update
Gilead highlights Yescarta survival data in ASCO update
Pharmaforum
Gilead Sciences
clinical trials
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
ASCO 2019
Flag link:
Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
Xconomy
cancer
CAR-T
Gilead Sciences
Yescarta
Novartis
Kymriah
Flag link:
2 Sets of Disasters Biotech Will Pay For in 2019
2 Sets of Disasters Biotech Will Pay For in 2019
Yahoo/Motley Fool
Gilead Sciences
Yescarta
Novartis
Kymriah
Spark Therapeutics
Luxturna
Flag link:
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah
Fierce Pharma
Gilead
Novartis
CAR-T
Yescarta
Kymriah
ASH2018
Flag link:
NHS, Gilead reach agreement for Yescarta
NHS, Gilead reach agreement for Yescarta
BioCentury
Yescarta
Gilead Sciences
UK
NHS
CAR-T
Flag link:
UK rejects Gilead's CAR-T cancer cell therapy as too expensive
UK rejects Gilead's CAR-T cancer cell therapy as too expensive
Reuters
Yescarta
UK
Europe
CAR-T
NICE
Gilead Sciences
Flag link:
Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma
Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma
CP Wire
Kite Pharma
Gilead Sciences
EMA
CHMP
Yescarta
B-cell lymphoma
Flag link:
Could an old Amgen-developed RA drug make CAR-T treatments safer?
Could an old Amgen-developed RA drug make CAR-T treatments safer?
Fierce Biotech
CAR-T
cytokine release syndrome
Kymriah
Yescarta
Amgen
Kineret
Flag link:
Gilead finds new home in Europe for CAR-T manufacturing
Gilead finds new home in Europe for CAR-T manufacturing
Biopharma Dive
Gilead Sciences
Netherlands
Yescarta
drug manufacturing
Flag link:
New approval sets up CAR-T showdown for Gilead, Novartis
New approval sets up CAR-T showdown for Gilead, Novartis
Biopharma Dive
Kymriah
Novartis
cell therapy
Yescarta
Gilead Sciences
Flag link:
Medicare sets outpatient rate for Yescarta reimbursement
Medicare sets outpatient rate for Yescarta reimbursement
Reuters
Medicare
Yescarta
reimbursement
Gilead Sciences
Flag link:
5 Drugs That Are Critical for Gilead Sciences' Future
5 Drugs That Are Critical for Gilead Sciences' Future
Motley Fool
Gilead Sciences
Biktarvy
Yescarta
selonsertib
filgotinib
Epclusa
Flag link:
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
Flag link:
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Endpoints
CAR-T
Gilead Sciences
Pfizer
utomilumab
Yescarta
large B-cell lymphoma
Flag link:
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Endpoints
Kymriah
Yescarta
CAR-T
Novartis
Kite Pharma
Gilead Sciences
drug pricing
Flag link:

Pages